Tethys Bioscience, Inc.

Tethys Bioscience, Inc. was established in 2002 with the mission to create and commercialize innovative blood tests to assess imminent disease risk. Their focus was on reducing the burden of preventable chronic diseases by preempting their development. The company's flagship product, PreDx® Diabetes Risk Score, was a fasting blood test that provided an unprecedented level of risk stratification for patients at risk for type 2 diabetes. Recent studies showed that a decrease in PreDx DRS correlated with a decreased risk of diabetes years later. Tethys aimed to build a sustainable cardiometabolic diagnostics business by expanding its commercial infrastructure and establishing partnerships to increase physician use. However, the company closed its doors in 2014, and its assets were acquired by Human Diagnostics Labs. The last recorded investment was a $12.00M Debt Financing investment on 01 January 2012, led by Armentum Partners. Tethys Bioscience operated in the Biotechnology and Health Care industries and was headquartered in the United States.